Lunai Bioworks (LNAI) Cash & Current Investments (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Cash & Current Investments of $3.2 million for Q1 2026, up 93.19% year-over-year from $1.6 million in Q1 2025, and up 541.78% quarter-over-quarter from $491645.0 in Q4 2025.
Lunai Bioworks (LNAI) Cash & Current Investments (2011 - 2026) Analysis & Trends
Lunai Bioworks' Cash & Current Investments history runs 16 years deep, the most recent figure standing at $3.2 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 93.19% year-over-year to $3.2 million; the TTM figure through Mar 2026 stood at $3.2 million (up 93.19% YoY), while the FY2025 annual figure was $480551.0, up 117.97% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $3.2 million, up from $491645.0 in the prior quarter.
- The five-year high for Cash & Current Investments was $11.2 million in Q1 2022, with the low at $220467.0 in Q2 2024.
- The 5-year median for Cash & Current Investments is $624808.0 (2025), against an average of $2.7 million.
- The sharpest annual moves came in 2023 and 2025: Cash & Current Investments plunged 94.08% in 2023, then jumped 422.32% in 2025.
- Lunai Bioworks' Cash & Current Investments stood at $4.1 million in 2022, then slumped by 94.08% to $243980.0 in 2023, then advanced by 27.78% to $311764.0 in 2024, then soared by 57.7% to $491645.0 in 2025, then soared by 541.78% to $3.2 million in 2026.
- Business Quant data shows LNAI's Cash & Current Investments at $3.2 million in Q1 2026, $491645.0 in Q4 2025, and $624808.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 3.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.16 Mn |
| Dec 31, 2025 | 491,645.00 |
| Sep 30, 2025 | 624,808.00 |
| Jun 30, 2025 | 480,551.00 |
| Mar 31, 2025 | 1.63 Mn |
| Dec 31, 2024 | 311,764.00 |
| Sep 30, 2024 | 220,571.00 |
| Jun 30, 2024 | 220,467.00 |
| Mar 31, 2024 | 312,697.00 |
| Dec 31, 2023 | 243,980.00 |
| Sep 30, 2023 | 523,474.00 |
| Jun 30, 2023 | 1.87 Mn |
| Mar 31, 2023 | 2.95 Mn |
| Dec 31, 2022 | 4.12 Mn |
| Sep 30, 2022 | 7.97 Mn |
| Jun 30, 2022 | 9.17 Mn |
| Mar 31, 2022 | 11.15 Mn |
| Dec 31, 2021 | 13.71 Mn |
| Sep 30, 2021 | 15.38 Mn |
| Jun 30, 2021 | 20.66 Mn |